Research programme: small molecule therapeutics - Regeneron Pharmaceuticals/AstraZeneca
Latest Information Update: 05 Aug 2021
At a glance
- Originator AstraZeneca; Regeneron Pharmaceuticals
- Class Obesity therapies; Small molecules
- Mechanism of Action G protein-coupled receptor modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Obesity